Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alderâs lead product candidate, eptinezumab, is a pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP). Eptinezumab is currently in late-stage clinical development and, if approved, will be the first-to-market infusion therapy for migraine prevention. Source
No articles found.
Unlimited Tomorrow is here to change the way we think about artificial limbs. They...
Unlimited Tomorrow is here to change the way we...
NextCure is a clinical-stage biopharmaceutical company committed to discovering an...
NextCure is a clinical-stage biopharmaceutical ...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
Join the National Investor Network and get the latest information with your interests in mind.